Skip to main content

AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail

AZD7442 is being evaluated for the prevention and treatment of COVID-19 in late-stage trials in more than 9,000 participants around the world.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.